Integra LifeSciences Holdings Corporation · NASDAQ:IART
Integra LifeSciences — Q3 2021 Earnings Presentation
22 slides from Integra LifeSciences's earnings presentation, Nov 2, 2021
Slide 1: Q3 2021 Earnings Presentation
Q3 2021 EARNINGS PRESENTATION NOVEMBER 2, 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of hist
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, free cash flow and adjusted fre
Slide 4: CEO Transition
CEO Transition Peter Arduini President & CEO
Slide 5: Jan De Witte Appointed Integra's Next President & CEO
Jan De Witte Appointed Integra’s Next President & CEO Experience • June 2016 – September 2021: CEO, Barco N.V. (Euronext: BAR), Visualization for health-tech and other markets. Performance “ turnaround, digital innovation, product management, I am honored and excited to be internationalization, oper
Slide 6: Operations Update
Operations Update Glenn Coleman EVP & COO
Slide 7: Integra Growth Catalysts
Integra Growth Catalysts Near- to Mid-Term Growth Catalysts Third Quarter Performance & Progress (Reviewed at May Investor Day) • Broad-based organic growth despite COVID-related variability Diverse and • Post-COVID procedure growth recovery Inclusive Teams • Strong international sales – led by Japa
Slide 8: Q3 2021 Financial Performance
Q3 2021 Financial Performance Carrie Anderson EVP & CFO
Slide 9: Q3 2021 Financial Results ($M except per share data)
Q3 2021 Financial Results ($M except per share data) Total Revenue Adj. Gross Profit Adj. EBITDA Adj. EPS Operating Cash Flow Reported 4.5% (30bps) Margin (90bps) Margin +7.5% +18.6% Organic 6.7% $45 0.0 $370.2 $386.9 1 $30 0.0 $254.1 $264.4 20 120 $103.2 $104.3 1.2 $0.9 0 $0.86 1.2 $10 0 $83 $40 0.
Slide 10: Codman Specialty Surgical
Codman Specialty Surgical Revenues Q3’21 Q3’20 Growth Reported $256.5M $239.3M 7.2% Q3 2021 Organic1 $253.6M $234.7M 8.0% Revenue Composition Q3 2021 Growth and Performance Drivers2 Instruments Neurosurgery Instruments International 22.3% 6.0% 15.5% + High Single Digits • Neurosurgery – sales in neu
Slide 11: Tissue Technologies
Tissue Technologies Revenues Q3’21 Q3’20 Growth Reported $130.4M $130.9M -0.4% Q3 2021 Organic1 $113.0M $109.0M 3.7% Revenue Composition Q3 2021 Growth and Performance Drivers2 Private Wound Reconstruction Private Label International Label 23.5% 1.7% 9.2% + Double Digits • Wound Reconstruction – sal
Slide 12: Balance Sheet and Cash Flow Performance
Balance Sheet and Cash Flow Performance Summary Balance Sheet ($M) 12/31/20 9/30/21 Operating Cash Flow, Free Cash Flow ($M) & Adj. FCF Conversion (%) FCF Capex Cash and Cash Equivalents $470 $470 350 $323.4 300 $29.0 Total Debt $1,663 $1,562 250 $212.8 Total Equity $1,515 $1,632 90 $82.8 200 80 $69
Slide 13: Q4 2021 and FY 2021 Revenue Outlook
Q4 2021 and FY 2021 Revenue Outlook Q4 Reported Revenue Guidance Bridge ($M) Q4 2021 Q3+ ($24) ~6.5% ~($5) • Revenue: Low end of $403-$413M range $403 - $413 $389 • Reported Growth ~3.5% • Organic Growth ~6.5% • Adj EPS $0.82 - $0.86 2021 Reported Revenue Guidance Bridge ($M) FY 2021 $65+ ($78) ~13%
Slide 14: Integra Well-Positioned to Accelerate Profitable Growth
Integra Well-Positioned to Accelerate Profitable Growth 01 02 03 04 05 At an inflection Reshaped and Driving deeper into Enablers of Clearer path to point to accelerate optimized portfolio current markets and transformation achieve long-term scale and market • Faster growth expanding into new • Oper
Slide 15: Appendix: Non-GAAP Reconciliations
Appendix Non-GAAP Reconciliations
Slide 16: Third Quarter Financial Results
Third Quarter Financial Results % of Revenues Q3 2021 Q3 2020 Change Q3 YTD 2021 Q3 YTD 2020 Change Total Revenues $386.9 $370.2 4.5% $1,136.9 $983.2 15.6% Gross Margin 62.7% 63.6% -90BPS 61.2% 62.0% -80BPS Adj. Gross Margin(1) 68.3% 68.6% -30BPS 67.9% 67.9% -0BPS Net Income $43.2 $32.3 33.7% $123.7
Slide 17: Third Quarter 2021 Organic Growth Reconciliation
Third Quarter 2021 Organic Growth Reconciliation (In millions) Q3 2021 Q3 2020 Q3 YTD 2021 Q3 YTD 2020 Neurosurgery $199.2 $189.7 $591.0 $516.1 Instruments $57.3 $49.6 $163.5 $124.5 Total Codman Specialty Surgical $256.5 $239.3 $754.5 $640.6 Wound Reconstruction and Care $99.7 $82.1 $291.0 $210.7 Ex
Slide 18: Third Quarter 2021 & 2020 Adjusted EBITDA Margin Reconciliation
Third Quarter 2021 & 2020 Adjusted EBITDA Margin Reconciliation (In millions) Q3 2021 Q3 2020 Q3 YTD 2021 Q3 YTD 2020 GAAP Net Income $43.2 $32.3 $123.7 $41.1 Depreciation 9.9 10.5 28.7 30.9 Intangible asset amortization 20.2 20.2 63.1 58.6 Other (income), net (3.4) (2.5) (10.6) (3.0) Interest expen
Slide 19: Third Quarter 2021 and 2020 Adjusted EPS Reconciliation
Third Quarter 2021 and 2020 Adjusted EPS Reconciliation Note: Numbers may not add due to rounding (In millions) Q3 2021 Q3 2020 Q3 YTD 2021 Q3 YTD 2020 GAAP Net Income $43.2 $32.3 $123.7 $41.1 COVID-19 related charges (0.0) (0.2) (0.0) 3.6 Convertible debt non-cash interest(1) - 4.3 - 11.1 Expenses
Slide 20: Third Quarter 2021 and 2020 (TTM) Adjusted Free Cash Flow Reconciliation
Third Quarter 2021 and 2020 (TTM) Adjusted Free Cash Flow Reconciliation Note: Numbers may not add due to rounding (In millions) Q3 2021 Q3 2020 TTM 2021 TTM 2020 Net Cash from Operating Activities $82.8 $69.6 $323.4 $212.8 Purchases of Property and Equipment ($7.3) ($6.7) ($29.0) ($52.7) Free Cash
Slide 21: Third Quarter 2021 Gross Margin Reconciliation
Third Quarter 2021 Gross Margin Reconciliation Note: Numbers may not add due to rounding (In millions) Q3 2021 Q3 2020 Q3 YTD 2021 Q3 YTD 2020 Reported Gross Profit $242.4 $235.4 $695.4 $609.5 COVID-19 related charges (0.0) 0.0 (0.0) 3.8 Structural optimization charges 3.0 0.5 6.1 2.4 Acquisition, d
Slide 22: Third Quarter 2021 Adjusted SG&A Reconciliation
Third Quarter 2021 Adjusted SG&A Reconciliation Note: Numbers may not add due to rounding (In millions) Q3 2021 Q3 2020 Q3 YTD 2021 Q3 YTD 2020 Reported SG&A $156.0 $150.1 $475.2 $432.1 COVID-19 related charges - (0.2) (0.0) (0.1) Structural optimization charges 2.2 3.9 5.2 6.5 Acquisition, divestit
Integra LifeSciences Holdings — Q3 2021 Earnings Presentation on 6ix